Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
37.86
-0.01 (-0.03%)
Aug 13, 2025, 4:00 PM - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Collegium Pharmaceutical stock ranges from a low of $37 to a high of $50. The average analyst price target of $44.25 forecasts a 16.88% increase in the stock price over the next year.
Price Target: $44.25 (+16.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +16.22% | Aug 11, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $36 → $37 | Hold | Reiterates | $36 → $37 | -2.27% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +21.50% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +32.07% | Mar 24, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $37 → $36 | Hold | Maintains | $37 → $36 | -4.91% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
760.70M
from 631.45M
Increased by 20.47%
Revenue Next Year
782.82M
from 760.70M
Increased by 2.91%
EPS This Year
7.03
from 1.86
Increased by 278.52%
EPS Next Year
7.16
from 7.03
Increased by 1.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 796.5M | 823.2M | 860.0M | ||
| Avg | 760.7M | 782.8M | 728.3M | ||
| Low | 724.7M | 732.4M | 576.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.1% | 8.2% | 9.9% | ||
| Avg | 20.5% | 2.9% | -7.0% | ||
| Low | 14.8% | -3.7% | -26.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.47 | 8.21 | 9.01 | ||
| Avg | 7.03 | 7.16 | 6.26 | ||
| Low | 6.62 | 6.22 | 3.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 302.1% | 16.9% | 25.8% | ||
| Avg | 278.5% | 1.9% | -12.6% | ||
| Low | 256.8% | -11.5% | -49.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.